270
Views
75
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: Prognostic value of TIMP-1 in severe sepsis

, , , , , , , , , , & show all
Pages 867-872 | Received 29 Dec 2005, Published online: 08 Jul 2009

References

  • Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993; 4: 197–250
  • Guedez L, Lim MS, Stetler-Stevensen WG. The role of metalloproteinases and their inhibitors in haematological disorders. Crit Rev Oncog 1996; 7: 205–25
  • Stetler-Stevenson WG, Liotta LA, Kleiner DE, Jr. Extracellular matrix 6: role of matrix metalloproteinases in tumour invasion and metastasis. FASEB J 1993; 7: 1434–41
  • Ferroni P, Basili S, Martini F, Cardarello CM, Ceci F, Di Franco M, et al. Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J Investig Med 2003; 51: 295–300
  • Keck T, Balcom JHT, Fernandez-del Castillo C, Bozena A, Antoniu BA, Warshaw AL. Matrix metalloproteinase-9 promotes neutrophil migration and alveolar capillary leakage in prancreatitis-associated lung injury in the rat. Gastroenterology 2002; 122: 188–201
  • Okada S, Kita H, George TJ, Gleich GJ, Leifermann KM. Migration of eosinophils through basement membrane components in vitro: role of matrix metalloproteinase-9. Am J Respir Cell Mol Biol 1997; 17: 519–28
  • Takeshita S, Tokotomi T, Kawase H, Nakatani K, Tsujimoto H, Kawamura Y, et al. Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease. Clin Exp Immunol 2001; 125: 340–4
  • Oshita Y, Koga T, Kamimura T, Matsuo K, Rikimaru T, Aizawa H. Increased circulating 92 kDa matrix metalloproteinase (MMP-9) activity in exacerbations of asthma. Thorax 2003; 58: 757–60
  • Ricou B, Nicod L, Lacraz S, Welgus HG, Suter PM, Dayer JM. Matrix metalloproteinases and TIMP in acute respiratory distress syndrome. Am J Respir Crit Care Med. 1996; 154: 346–52
  • Pugin J, Widmer MC, Kossodo S, Liang CM, Preas II HL, Suffredini AF. Human neutrophils secrete geatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Respir Cell Mol Biol 1999; 20: 458–64
  • Albert J, Radomski A, Soop A, Sollevi A, Frostell C, Radomski MW. Differential release of matrix metalloproteinase-9 and nitric oxide following infusion of endotoxin to human volunteers. Acta Anaesthesiol Scand. 2003; 47: 407–10
  • Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101: 1644–55
  • Knaus WA, Draper EA, Wagner D, Zimmermann JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818–29
  • Opdenakker G, van den Stehen PHE, van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends in Immunology 2001; 22: 571–9
  • Goetzl EJ, Banda MJ, Leppert D. Matrix metalloproteinases in immunity. J Immunol 1996; 165: 1–4
  • Matsuyama A, Sakai N, Ishigami M, Hiraoka H, Kashine S, Hirata A, et al. Matrix metalloproteinases as novel disease markers in Takayasu arteritis. Circulation 2003; 108: 1469–73
  • Spittler A, Razenberger M, Kupper H, Kaul M, Hackl W, Boltz-Nitulescu G, et al. Relationship between interleukin-6 plasma concentration in patients with sepsis, monocyte phenotype, monocyte phagocytic properties, and cytokine production. Clin Infect Dis. 2000; 31: 1338–42
  • Remick DG, Bolgos G, Copeland S, Siddiqui J. Role of interleukin-6 in mortality from and physiological response to sepsis. Infect Immun 2005; 73: 2751–7
  • Nakamura T, Ebihara I, Shimada N, Shoji H, Koide H. Modulation of plasma metalloproteinase-9 concentrations and peripheral blood monocyte mRNA levels in patients with septic shock: effect of fibre-immobilized polymyxin B treatment. Am J Med Sci. 1998; 316: 355–60
  • Yassen KA, Galley HF, Webster NR. Matrix metalloproteinase-9 concentrations in critically ill patients. Anaesthesia 2001; 56: 729–32
  • Chromek M, Tullus K, Lundahl J, Brauner A. Tissue inhibitor of metalloproteinase 1 activates normal human granulocytes, protects them from apoptosis, and blocks their transmigration during inflammation. Infection and Immunity 2004; 72: 82–8
  • Tayebjee MH, Lip GYH, Blann AD, MacFadyen RJ. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. Thrombosis Research 2005; 115: 205–10
  • Dubois B, Starckx S, Pagenstecher A, van den Oord J, Arnold B, Opdenakker G. Gelatinase B deficiency protects against endotoxin shock. Eur J Immunol 2002; 32: 2163–71
  • Lalu MM, Gao CQ, Schulz R. Matrix metalloproteinase inhibitors attenuate endotoxaemia induced cardiac dysfunction: a potential role for MMP-9. Mol Cell Biochem 2003; 251: 61–6

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.